{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:09:06Z","timestamp":1648674546081},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.diagmicrobio.2004.12.004","type":"journal-article","created":{"date-parts":[[2005,3,11]],"date-time":"2005-03-11T12:26:37Z","timestamp":1110543997000},"page":"95-99","source":"Crossref","is-referenced-by-count":3,"title":["Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum \u03b2-lactamase\u2013producing organisms"],"prefix":"10.1016","volume":"52","author":[{"given":"Sudha","family":"Pottumarthy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalitagauri M.","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum \u03b2-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib2","series-title":"Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003","article-title":"Impact of ESBLs on in vivo activity of four cephalosporins in the neutropenic mouse-thigh infection model","author":"Craig","year":"2003"},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib3","series-title":"Prescribing information for Maxipime\u00ae","year":"2004"},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/AAC.27.5.679","article-title":"Evaluation of in-vitro activity of BMY-28142, a new broad-spectrum cephalosporin","volume":"27","author":"Fuchs","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/JCM.23.3.634-636.1986","article-title":"Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin","volume":"23","author":"Fuchs","year":"1986","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkg312","article-title":"European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria","volume":"52","author":"Kahlmeter","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib7","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.48.6.1941-1947.2004","article-title":"Determination of the in-vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula","volume":"48","author":"Maglio","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib8","series-title":"Development of in vitro susceptibility testing criteria and quality control parameters. Approved standard","year":"2001"},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib9","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard","year":"2003"},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib10","series-title":"Methods for antimicrobial disk susceptibility tests. Approved standard","year":"2003"},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib11","series-title":"Performance standards for antimicrobial susceptibility testing. 14th Informational supplement","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib12","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: Implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/JCM.42.1.269-275.2004","article-title":"Effects of the inoculum and \u03b2-lactamase activity in AmpC- and extended-spectrum \u03b2-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology","volume":"42","author":"Queenan","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib14","first-page":"369","article-title":"Cefepime: The next generation?","volume":"17","author":"Sanders","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3201\/eid0702.010238","article-title":"Controversies about extended-spectrum and ampC beta-lactamases","volume":"7","author":"Thomson","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2004.12.004_bib16","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889304002639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889304002639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T08:42:43Z","timestamp":1586162563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889304002639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0732889304002639"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2004.12.004","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}